Nura Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing neuroprotective small-molecule medicines that halt neurodegeneration before it progresses. Conceived in 2018 by The Column Group together with scientific founders Steve McKnight, PhD and Marc Freeman, PhD, the company targets SARM1 — a neuronally enriched NAD hydrolase that acts as an axon-intrinsic metabolic sensor and central driver of axonal degeneration — on the thesis that intervening early in that pathway confers durable structural and functional neuroprotection across peripheral, central and ocular nervous-system disorders. Its pipeline is led by NB-4746, a first-generation oral, brain-penetrant, reversible orthosteric SARM1 inhibitor in a global Phase 1b/2a study in ALS, and NB-9402, a mechanistically differentiated second-generation oral, covalent, irreversible, allosteric inhibitor completing a Phase 1a healthy-volunteer study in 2026. Nura Bio launched publicly in January 2020 with a $73 million Series A, extended that round with $68 million to pass $140 million raised, and closed a $73.8 million Series B in June 2026 led by The Column Group with Euclidean Capital, Samsara BioCapital and Sanofi Ventures; Shilpa Sambashivan, PhD, a co-founder and its chief scientist, serves as CEO. Its science is published in NEURON and CELL REPORTS. Nura Bio runs no developer program and publishes no product API, developer portal, API reference, SDK or pricing. The only machine-readable surfaces reachable without credentials are a published llms.txt and the WordPress REST content API behind nurabio.com, which serves the news archive, site pages, people directory and media library as JSON — both catalogued here.
Nura Bio publishes 7 APIs on the APIs.io network, including Directory API, Discovery API, Media API, and 4 more. Tagged areas include Company, Biotechnology, Pharmaceuticals, Neuroscience, and Neurodegeneration.
Nura Bio’s developer surface includes product news, authentication, and 19 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics does not apply to this provider. The published contracts declare
no write operations, and a read-only API cannot create-or-update. The facet is excluded from this provider's
denominator entirely — not scored zero. A reference or data API is not deficient for being unable to
upsert.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/nura-bio: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
The people directory — leadership, board of directors, and founders and advisors — carried on the Avada theme `portfolio` custom post type and its `portfolio_entries` taxonomy.
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →